Edition:
United States

Nanobiotix SA (NANOB.PA)

NANOB.PA on Paris Stock Exchange

15.08EUR
11:37am EDT
Change (% chg)

€5.03 (+50.05%)
Prev Close
€10.05
Open
€16.46
Day's High
€16.50
Day's Low
€14.66
Volume
1,652,199
Avg. Vol
93,554
52-wk High
€20.90
52-wk Low
€8.30

Chart for

About

Nanobiotix SA is a France-based oncology focused nanomedicine company. It is engaged in developing nanoparticle technology. It develops new tools for cancer which utilize a physical mode of action at the cellular level of the cancer cell. This disruptive approach may reshape future treatment opportunities. The Company's NanoXray... (more)

Overall

Beta: 1.82
Market Cap(Mil.): €201.44
Shares Outstanding(Mil.): 19.63
Dividend: --
Yield (%): --

Financials

  NANOB.PA Industry Sector
P/E (TTM): -- 244.60 33.54
EPS (TTM): -1.50 -- --
ROI: -74.41 -5.33 13.09
ROE: -85.27 -6.88 15.10

BRIEF-Nanobiotix Did Not Generate Any Revenue In Q1

* ANNOUNCED ON TUESDAY IT DID NOT GENERATE ANY REVENUE FOR Q1 2018, AS IT HAD EXPECTED

May 16 2018

BRIEF-Nanobiotix Partners With Weill Cornell Medicine

* PARTNERSHIP ON PRE-CLINICAL STUDIES TO EVALUATE NBTXR3 IMPACT ON CGAS-STING PATHWAY IN MAMMARY CANCERS

May 03 2018

BRIEF-Nanobiotix FY Net Loss Widens to ‍​26.1 Million Euros

* TOTAL REVENUE IN 2017 AMOUNTS TO EUR 3.7M VERSUS. EUR 5.4M IN 2016

Mar 30 2018

BRIEF-Nanobiotix Presents Data From Phase I/II Liver Cancers Trial Of NBTXR3

* NANOBIOTIX PRESENTS FIRST PROMISING DATA FROM PHASE I/II LIVER CANCERS TRIAL OF NBTXR3 AT THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY GASTROINTESTINAL ANNUAL MEETING

Jan 22 2018

BRIEF-Nanobiotix Partners With The Providence Cancer Institute To Run Immunotherapeutic Preclinical Research In Pancreatic Cancers

* NANOBIOTIX PARTNERS WITH THE PROVIDENCE CANCER INSTITUTE TO RUN IMMUNOTHERAPEUTIC PRECLINICAL RESEARCH IN PANCREATIC CANCERS

Jan 11 2018

BRIEF-Nanobiotix: FDA Approves First Immuno-Oncology Trial

* NANOBIOTIX : FDA APPROVES NANOBIOTIX'S FIRST IMMUNO-ONCOLOGY TRIAL

Dec 26 2017

Earnings vs. Estimates